Hanger : May 2022 Corporate Presentation

President & CEO

Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statement in this document that is not a historical fact is a "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act and are usually identified by the use of words such as "anticipates," "believes," "estimates," "expects," "intends," "may," "plans," "projects," "seeks," "should," "will," and variations of such words or similar

expressions. We intend these forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, and are making this statement for purposes of complying with those safe harbor provisions. These forward- looking statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control.

Risks and uncertainties for Plus include, but are not limited to: an inability or delay in obtaining required regulatory approvals for product candidates, which may result in unexpected cost expenditures; risks inherent in drug development in general; uncertainties in obtaining successful clinical results for product candidates and unexpected costs that may result therefrom; failure to realize any value of certain product candidates developed and being developed in light of inherent risks and difficulties involved in successfully bringing product candidates to market; inability to develop new product candidates and support existing products; the approval by the FDA and any other similar foreign regulatory authorities of other competing or superior products brought to market; risks resulting from unforeseen side effects; risk that the market for the combined company's products may not be as large as expected; inability to obtain, maintain and enforce patents and other intellectual property rights or the unexpected costs associated

with such enforcement or litigation; inability to obtain and maintain commercial manufacturing arrangements with third-party manufacturers or establish commercial scale manufacturing capabilities; loss of or diminished demand from one or more key customers or distributors; unexpected cost increases and pricing pressures; economic recession and its negative impact on customers, vendors or suppliers; uncertainties of cash flows, expenses and inability to meet working capital needs; and other risks and uncertainties detailed in the risk factors section of Plus' Form 10-K and Forms 10-Q filed with the SEC, as well as other filings Plus makes with the SEC from time-to-time. Many of these factors that will determine actual results are beyond Plus' ability to control or predict. Plus disclaims any obligation to update information contained in these forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

We believe in the critical importance in developing and delivering innovative, targeted radiotherapeutics for patients battling rare and CNS cancers.

Radiopharmaceuticals for Cancer

"Compelling Next-Gen Approach for Solid Tumors"

"Theoretically, any cancer can be cured if enough radiation can be delivered to it."

Dr. Andrew Brenner

Kolitz/Zachry Endowed Chair Neuro-Oncology Research

UT Health San Antonio

Professor Neuro Oncology & Neurosurgery

"In 2016, there were an estimated 3.05 million cancer survivors treated with radiation, accounting for 29% of all cancer survivors."

Cancer Epidemiol Biomarkers Prev 2017 Jun;26(6):963-970

Rare and Difficult-to- Treat Cancers

Glioblastoma: deadliest, most common brain cancer in adults (TAM $2.1B)

Responsible for Substantial Morbidity and Mortality Worldwide

Leptomeningeal Metastases: late complication in 5% of cancer patients (TAM $8.4B)

+ Rare cancers represent 27% of all cancers; all pediatric cancers are rare

Pediatric Brain Cancer: 2nd most common type of cancer in children (TAM $106M)

+ Rare cancers account for 25% of all cancer deaths; 5-year survival rate is lower for patients with a rare cancer than those with a more common cancer

+ Treatments for rare cancers are eligible for orphan drug designations

Sources: CBTRUS Statistical Report, NBTS, NCI

186RNL FOR CNS TUMORS

188BAM FOR LIVER & SOLID TUMORS

Primary Liver Cancer: 42k cases diagnosed annually in U.S. with 5-year survival of 20%

Secondary Liver Cancer: ~50-60% of colorectal cancer patients develop metastases to liver (TAM $1.3B)